Moses Lake Pharmacy Recalls Dihydroergotamine Mesylate Injectable Syringes
JD & SN Inc. is recalling 8 syringes of Dihydroergotamine Mesylate Injectable Solution due to a lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility in an injectable drug, which poses a significant risk of serious injury or infection.
Plain-English summary
JD & SN Inc., doing business as Moses Lake Professional Pharmacy, is recalling 8 syringes of Dihydroergotamine Mesylate Injectable Solution, 1 mg/mL, 20 mL. The product is a prescription-only injectable solution distributed nationwide.
The recall was initiated because of a lack of assurance of sterility for all sterile human compounded drugs within their expiry dates. The specific lot codes associated with this recall are t02162015@9, t04132015@10, t05192015@15, t07062015@20, t07242014@11, t08292014@13, t11212014@17, and t12312014@15.
Consumers who have this product should stop using it and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- DIHYDROERGOTAMINE MESYLATE, Injectable Solution, 1 MG/ML, 20 mL syringe, Rx only, JD & SN Inc, DBA Moses Lake Professional Pharmacy, 1555 S. Pilgrim St. Moses Lake WA 98837, (509)764-2314
- Category
- Drug — Injectable Solution
- Affected units
- 8
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- t02162015@9
- t04132015@10
- t05192015@15
- t07062015@20
- t07242014@11
- t08292014@13
- t11212014@17
- t12312014@15.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 101 recalled by JD & SN Inc., dba Moses Lake Professional Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 101 products in this recall →Related recalls
Same manufacturer · JD & SN Inc., dba Moses Lake Professional Pharmacy
See all →- SevereFDA Recalls Estradiol Pellets Due to Lack of Sterility Assurance
FDA (Drugs) · 2015-11-04
- SevereFDA Recalls Sodium Tetradecyl Sulfate Syringes Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereMoses Lake Pharmacy Recalls Six Trimix Syringes Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereMoses Lake Pharmacy Recalls Compounded Chorionic Gonadotropin Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereFDA Recalls Compounded Progesterone Pellets Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- HighMartin Avenue Pharmacy Recalls Dihydroergotamine Mesylate Injection Due to Sterility Concerns
FDA (Drugs) · 2014-11-05
- SevereEdge Pharma Recalls Methotrexate Syringes Due to Sterility Testing Concerns
FDA (Drugs) · 2021-01-20
- SevereMoxifloxacin Ophthalmic Injection Syringes Recalled for Sterility Risk
FDA (Drugs) · 2022-02-02
- SeverePremier Pharmacy Labs Recalls Dexamethasone Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-07-03
- SevereNeostigmine Methylsulfate Injectable Syringes Recalled for Sterility Assurance
FDA (Drugs) · 2022-02-02
- SevereRXQ Compounding Recalls Midazolam Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14